BG MEDICINE ANNOUNCES AGREEMENT WITH BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

BG Medicine announced today that it has entered into an agreement with Boehringer Ingelheim Pharmaceuticals, Inc. BG Medicine will apply its Systems Pharmacology platform to elucidate tissue drug effects and discover circulating biomarkers for clinical application. BG Medicine will take a systems biology approach employing multiple platforms to generate data for analyses in proprietary bioinformatics and statistical methods. Financial terms of the agreement were not disclosed.

BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050728005607&ndmHsc=v2*A1121943600000*B1122590479000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)